kaposi
sarcoma
ks
angioprolif
disord
viral
etiolog
multifactori
pathogenesi
hing
immun
dysfunct
diseas
multifoc
cours
rang
indol
skin
manifest
fulmin
extens
viscer
involv
current
view
form
ks
common
etiolog
human
herpesviru
hhv
infect
differ
among
due
involv
variou
cofactor
fact
infect
consid
necessari
suffici
condit
develop
ks
factor
genet
immunolog
environment
requir
role
cofactor
attribut
abil
interact
affect
immun
system
act
vasoact
agent
contribut
survey
current
state
knowledg
mani
variou
factor
involv
ks
pathogenesi
carri
particular
highlight
fact
controversi
role
drug
quinin
analogu
angiotensinconvert
enzym
inhibitor
onset
diseas
base
assess
possibl
hypothes
role
cofactor
ks
pathogenesi
move
toward
effect
either
favor
inhibit
onset
diseas
depend
presenc
agent
modul
pathogenesi
genet
predisposit
environment
factor
drug
intak
lymph
flow
disord
possibl
agent
may
act
either
stimul
inhibit
cofactor
accord
patient
genet
background
variabl
interact
treatment
guidelin
form
ks
outlin
uniqu
standard
therapi
consid
due
ks
heterogen
case
therapeut
option
local
system
tailor
patient
peculiar
clinic
condit
kaposi
sarcoma
ks
angioprolif
diseas
viral
etiolog
multifactori
pathogenesi
hing
immun
dysfunct
name
bound
moritz
kaposi
kaposi
describ
three
fatal
case
multipl
idiopath
pigment
hemangiosarcoma
elderli
men
univers
vienna
sinc
ks
defin
malign
neoplasm
blood
lymph
vessel
present
multipl
vascular
nodul
skin
organ
diseas
multifoc
cours
rang
indol
skin
manifest
fulmin
extens
viscer
involv
sinc
kaposi
descript
classic
type
clinician
describ
four
distinct
type
although
classic
type
remain
preval
among
elderli
men
mediterranean
origin
diagnos
worldwid
typic
follow
benign
cours
african
endem
form
ks
first
describ
occur
predominantli
among
young
black
men
age
year
also
lymphadenopath
subvari
african
form
affect
children
mean
age
year
third
form
associ
immunosuppress
treatment
describ
among
recipi
organ
transplant
patient
longterm
corticosteroid
variou
disord
patient
immunosuppress
result
therapeut
regimen
includ
chemotherapi
iatrogen
form
final
epidem
ks
among
young
men
sex
men
unit
state
serv
harbing
new
immunodefici
syndrom
subsequ
identifi
associ
hiv
infect
epidem
form
hiv
epidem
progress
ks
found
almost
exclus
among
homosexu
men
due
epidemiolog
data
indic
high
incid
ks
among
person
greater
risk
sexual
transmit
infect
independ
infecti
agent
propos
etiolog
epidem
ks
etiolog
pathogenesi
ks
viral
etiolog
hypothesi
discoveri
although
onset
ks
ensu
complex
multifactori
event
includ
immunosuppress
crucial
role
viral
agent
suppos
sinc
specif
role
herpesvirus
propos
giraldo
colleagu
observ
herpestyp
viral
particl
five
eight
tissu
cultur
cell
line
african
patient
ks
subsequ
cytomegaloviru
genet
sequenc
identifi
tumor
major
breakthrough
etiolog
ks
report
chang
cowork
identifi
new
human
herpesviru
represent
differ
analysi
detect
viru
ks
lesion
includ
unrel
hiv
subsequ
document
ks
patient
four
type
ks
found
saliva
semen
may
spread
contact
saliva
kiss
well
sexual
activ
similarli
occur
herpesvirus
preval
antibodi
increas
age
show
wide
fluctuat
geograph
low
rate
b
seropreval
report
north
europ
america
high
rate
sicili
high
botswana
rate
usual
relat
preval
ks
nevertheless
countri
brazil
gambia
ivori
coast
thailand
high
seropreval
low
incid
ks
phylogenet
studi
perform
wellconserv
open
read
frame
orf
minor
capsid
gene
allow
identif
eight
distinct
subtyp
design
ac
j
km
de
b
q
r
n
group
divers
distribut
differ
geograph
region
particular
four
subtyp
b
n
q
r
found
almost
exclus
among
subsaharan
african
sampl
one
de
found
within
indigen
south
asian
polynesian
pacif
rim
popul
three
ac
j
k
identifi
almost
exclus
eurasian
subject
european
unit
state
north
asian
middl
eastern
sequenc
analysi
highli
variabl
orf
region
allow
identif
seven
major
subtyp
b
c
e
f
z
compris
sever
subclad
whose
distribut
world
parallel
orf
variant
subtyp
b
predomin
africa
f
identifi
ugandan
bantu
tribe
subtyp
present
pacif
island
subtyp
e
cluster
ancient
popul
like
brazilian
amerindian
wherea
c
predomin
europ
unit
state
still
unclear
whether
differ
genotyp
may
differ
pathogen
tumorigen
properti
associ
invers
rate
diseas
progress
role
cofactor
ks
pathogenesi
pathogenrel
diseas
clinic
outcom
infect
patient
subset
develop
chronic
infect
smaller
subset
progress
cancer
suggest
cofactor
need
differ
evolut
includ
genet
environment
determin
current
view
form
ks
common
etiolog
infect
differ
due
involv
cofactor
infect
fact
consid
necessari
suffici
condit
develop
ks
factor
genet
immunolog
environment
requir
well
known
today
necessari
caus
develop
ks
given
heterogen
distribut
viru
incid
ks
differ
popul
datum
small
percentag
seroposit
patient
develop
ks
genet
environment
cofactor
clearli
necessari
develop
tumor
similar
dna
oncogen
virus
express
viral
gene
directli
indirectli
perturb
protein
function
therebi
mediat
viral
oncogenesi
protein
play
central
role
cell
cycl
control
abil
induc
cell
cycl
arrest
dna
repair
senesc
apoptosi
respons
varieti
stimuli
stress
signal
genotox
agent
hypoxia
oncogen
activ
key
function
oncogenesi
tumor
suppressor
protein
support
fact
frequent
mutat
gene
varieti
human
cancer
divers
histolog
type
viru
interfer
pathway
sever
level
latencyassoci
nuclear
antigen
encod
orf
genom
suppress
transcript
transactiv
activ
interact
directli
protein
inhibit
abil
induc
cell
death
viral
interferon
ifn
regulatori
factor
encod
specif
interact
stabil
murin
doubl
minut
human
homologu
wellknown
neg
regul
via
proteasomemedi
degrad
lead
consequ
reduct
level
therebi
concur
suppress
apoptosi
relev
interfer
protein
strongli
support
relev
cell
cycl
control
number
studi
shown
overexpress
sever
human
cancer
higher
express
level
mutual
exclus
respect
mutat
suggest
may
substitut
mutat
inactiv
natur
occur
g
sequenc
variat
singlenucleotid
polymorph
second
promoterenhanc
region
gene
shown
increas
bind
affin
transcript
activ
result
high
level
protein
format
transcript
inact
complex
alter
pathway
observ
consist
oncogen
function
variant
polymorph
may
associ
earlier
onset
breast
cancer
lifraumeni
patient
earlier
onset
soft
tissu
sarcoma
diffus
larg
bcell
lymphoma
colorect
cancer
nonsmal
cell
lung
cancer
particularli
women
recent
studi
signific
increas
heterozyg
tg
genotyp
among
white
classic
ks
case
report
homozyg
gg
genotyp
classic
ks
hand
lower
observ
control
decreas
frequenc
gg
genotyp
cutan
ks
patient
could
sever
explan
includ
gg
carrier
infect
could
increas
risk
develop
viscer
ks
highli
aggress
relat
lymphoprolif
disord
primari
effus
lymphoma
pel
multicentr
castleman
diseas
analysi
seven
pel
cell
line
mutat
snp
gene
involv
apoptosi
cell
cycl
regul
includ
codon
gene
demonstr
interestingli
three
epsteinbarr
viru
ebv
neg
cell
line
name
bcp
homozyg
g
suggest
major
role
polymorph
allel
cell
transform
particularli
absenc
ebv
coinfect
futur
research
howev
need
accur
address
hypothesi
immun
deficit
risk
ks
system
immunodefici
ks
preval
tremend
higher
posttranspl
aid
patient
time
time
respect
greater
gener
popul
incid
ks
chang
markedli
aid
epidem
particularli
across
african
contin
hiv
epidem
ks
diseas
primarili
affect
men
extrem
incid
variat
among
specif
popul
differ
geograph
region
uganda
ks
repres
male
cancer
patient
respect
rare
femal
case
howev
ks
preval
male
cancer
patient
rose
incid
becom
frequent
report
cancer
men
wherea
preval
femal
cancer
patient
climb
incid
sinc
hiv
epidem
ks
becom
common
women
men
preval
also
mani
african
countri
almost
unknown
shown
preval
observ
point
role
factor
etiolog
ks
includ
possibl
differ
variant
might
spread
hivaid
epidem
local
immunodefici
concern
immun
disord
system
immunodefici
consid
well
condit
local
immun
destabil
lymphedema
caus
sever
agent
often
environment
factor
endem
ks
relationship
ks
podoconiosi
nonfilari
elephantiasi
increas
preval
ks
among
rural
peasant
cultiv
toil
highland
soil
contain
volcan
clay
miner
walk
barefoot
volcan
soil
expos
pore
sweat
gland
bare
feet
permit
abras
allow
aluminosil
possibl
iron
oxid
taken
lymphat
silic
caus
obstacl
lymph
flow
inflamm
region
lymph
node
disrupt
immun
control
feet
leg
result
site
becom
immunocompromis
district
name
bodi
region
chronic
lymph
stasi
lead
immun
stasi
respons
local
outbreak
opportunist
infect
parasit
bacteri
fungal
tumor
paradigmat
ks
link
impair
lymph
circul
region
immun
dysfunct
classic
ks
first
proven
ks
appear
lymphedemat
leg
patient
alter
lymph
drainag
lack
cell
immun
respons
confin
lymphedemat
limb
intraderm
skin
test
common
antigen
perform
four
limb
forearm
leg
reveal
immun
respons
affect
limb
versu
normal
even
strong
respons
three
unaffect
limb
five
year
later
patient
present
lymphedema
new
ks
lesion
leg
occas
skin
test
neg
leg
wherea
normal
respons
still
observ
forearm
two
year
later
ks
lesion
also
appear
forearm
time
skin
test
neg
four
limb
lympholog
immunolog
investig
perform
patient
classic
ks
sensit
dinitrochlorobenzen
prove
affect
limb
present
concomit
alter
lymph
drainag
immun
respons
role
chronic
lymphedema
facilit
onset
ks
stress
unusu
local
peni
classic
form
even
epidem
aidsrel
type
although
rare
emphas
hivrel
ks
variabl
degre
lymphedema
overt
subtl
sort
microlymphedema
ksinvolv
area
somewhat
common
homosexu
men
wide
anatom
distribut
often
without
notabl
lymphadenopathi
also
local
trauma
may
respons
facilit
onset
ks
lesion
select
traumat
area
environment
cofactor
risk
ks
cancer
pathogenesi
possibl
exist
follow
initi
stabl
genet
damag
initi
event
transient
postiniti
insult
promot
event
nonsuffici
induc
cancer
could
contribut
increas
cancer
incid
virus
like
chemic
act
initi
well
promot
depend
preval
effect
either
mutagen
eg
herpesvirus
epigenet
eg
papillomavirus
virus
interact
sever
cocarcinogen
may
act
simultan
sequenti
continu
repeatedli
occasion
cocarcinogen
may
act
directli
potenti
cancer
cell
indirectli
affect
tissu
host
ks
repres
good
model
interact
differ
oncogen
factor
use
identifi
role
mechan
role
cofactor
attribut
abil
interact
affect
immun
system
act
vasoact
agent
tabl
aidsrel
ks
instanc
use
larg
quantiti
nitrit
inhal
among
gay
men
aid
strongli
associ
ks
onset
sever
plausibl
biolog
mechan
action
propos
nitrit
metabolit
cholesteryl
nitrit
nitrosamin
carcinogen
nitrit
inhal
use
might
also
contribut
develop
ks
immun
suppress
affect
small
blood
vessel
drug
environment
cofactor
risk
ks
fact
controversi
drug
prove
associ
ks
pathogenesi
due
immunomodulatori
proangiogen
effect
quinin
analogu
drug
use
mani
year
malaria
treatment
link
drug
ks
base
seri
clue
take
account
geograph
distribut
incid
ks
patient
take
drug
fact
seroposit
ks
high
preval
area
subsaharan
africa
itali
greec
low
northern
europ
asia
reflect
pattern
distribut
malaria
region
world
brazil
gambia
ivori
coast
thailand
high
seropreval
ks
malaria
rare
use
quinin
deriv
low
thu
confirm
possibl
associ
drug
ks
develop
sever
region
subsaharan
africa
despit
widespread
resist
plasmodium
quinolin
avail
efficaci
antimalari
drug
quinin
analogu
continu
wide
use
treatment
malaria
fact
sinc
african
countri
recommend
quinin
secondlin
treatment
uncompl
malaria
firstlin
treatment
sever
malaria
treatment
malaria
first
trimest
pregnanc
africa
quinin
still
use
monotherapi
contrari
recommend
world
health
organ
quinin
continu
play
signific
role
manag
malaria
subsaharan
africa
malaria
endem
area
use
routin
practic
may
restrict
state
recommend
cameroon
quinin
continu
use
firstlin
therapi
adult
receiv
oral
quinin
uncompl
malaria
recent
surveil
data
sentinel
site
uganda
show
quinin
prescrib
children
younger
age
year
uncompl
malaria
furthermor
drug
analog
wide
distribut
healthi
children
prevent
treatment
prophylaxi
campaign
still
widespread
use
antimalari
might
contribut
high
incid
ks
geograph
area
ks
malaria
endem
fact
ks
caus
agent
distinct
geograph
distribut
larg
unexplain
reason
put
forward
oncowe
hypothesi
suggest
environment
cofactor
plant
natur
product
deriv
present
ks
endem
region
may
caus
frequent
reactiv
infect
subject
thu
lead
increas
viral
shed
transmiss
convers
hypothes
quinin
deriv
might
better
explain
epidemiolog
ks
oncowe
oncodrug
hypothesi
specif
hint
quinin
deriv
fact
worth
note
quinin
chloroquin
hydroxychloroquin
may
affect
effect
immun
respons
immunosuppress
drug
well
known
chloroquin
hydroxychloroquin
extens
use
treatment
autoimmun
diseas
lupu
erythematosu
rheumatoid
arthriti
immunesuppress
properti
drug
may
produc
deleteri
effect
presenc
viral
infect
immun
exampl
random
control
trial
evalu
antibodi
respons
freshman
veterinari
student
intraderm
human
diploidcel
rabi
vaccin
administ
concurr
chloroquin
demonstr
drug
taken
dose
recommend
malaria
prophylaxi
reduc
antibodi
respons
primari
immun
rabi
vaccin
incident
one
could
reason
think
unusu
sever
cours
run
spanish
flu
pandem
could
facilit
document
larg
administr
quinin
flu
patient
time
quinin
consid
specif
remedi
fever
attack
quinin
also
use
cut
heroin
contribut
widespread
use
drug
among
heroin
addict
aidsrel
ks
drug
addict
repres
one
main
popul
risk
individu
use
quinin
combin
heroin
pave
way
onset
ks
due
interrel
antiinflammatori
immunosuppress
effect
two
drug
anoth
categori
drug
angiotensinconvert
enzym
ace
inhibitor
wide
associ
classic
iatrogen
ks
onset
sever
case
report
literatur
would
indic
ace
inhibitor
might
act
trigger
develop
ks
fact
ace
inhibitor
immmunomodulatori
effect
immunomodulatori
action
ace
inhibitor
attribut
sever
mechan
includ
inhibit
product
proinflammatori
cytokin
tumor
necrosi
factor
tnf
interleukin
il
produc
activ
monocyt
dendrit
cell
b
antiprolif
activ
c
inhibit
free
radic
inhibit
metalloproteas
e
elev
immunomodulatori
prostaglandin
suppress
ace
may
explain
immun
alter
possibl
immunosuppress
ace
shown
involv
immun
function
upregul
inflammatori
condit
furthermor
ace
inhibit
enhanc
angiogenesi
activ
pathway
proangiogen
effect
may
associ
upregul
endotheli
nitric
oxid
synthas
eno
express
would
independ
vascular
endotheli
growth
factor
vegf
pathway
studi
howev
confirm
eno
upregul
would
abl
stimul
vegf
pathway
stimul
angiogenesi
product
proinflammatori
cytokin
activ
evalu
role
cofactor
outbreak
ks
easi
task
exampl
contradictori
data
make
difficult
assess
relationship
exist
antimalari
drug
ks
tabl
chloroquin
hydroxychloroquin
quinin
analog
recent
consid
potenti
anticanc
agent
well
chemosensit
use
combin
anticanc
drug
colon
cancer
cell
topotecan
lung
cancer
cell
possibl
inhibit
autophagydepend
resist
chemotherapi
autophagi
evolutionarili
conserv
cell
surviv
pathway
implic
potenti
mechan
resist
anticanc
agent
fact
promot
cell
surviv
face
stress
induc
chemotherapeut
agent
break
cellular
compon
gener
altern
sourc
energi
disrupt
autophagi
chloroquin
induc
accumul
ubiquitinconjug
protein
stimul
apoptosi
sever
cancer
cell
chloroquin
hydroxychloroquin
also
inhibit
angiogenesi
product
proinflammatori
cytokin
vegf
fibroblast
growth
factor
fgf
transform
growth
cytokin
involv
reactiv
lytic
cycl
induct
microenviron
necessari
lesion
format
character
triad
inflamm
angiogenesi
product
cytokin
chemokin
thu
drug
counteract
molecular
target
abl
caus
diseas
indirectli
inhibit
action
viru
even
complex
evalu
direct
effect
exert
antimalari
drug
fact
chloroquin
hydroxychloroquin
lysosomotrop
amin
substanc
select
taken
lysosom
owe
accumul
drug
abl
increas
intracellular
ph
inhibit
phdepend
step
duplic
sever
bacteria
enterobacterium
agglomeran
staphylococcu
aureu
replic
virus
includ
member
flavivirus
retrovirus
coronavirus
herpesvirus
blockad
bacteri
viral
entri
via
inhibit
endosom
acidif
sever
studi
shown
entri
block
inhibit
acidif
endosom
also
problemat
role
fact
factor
seem
play
key
role
lytic
cycl
reactiv
viru
stimul
product
creat
ideal
environ
genesi
diseas
antimalari
drug
seem
abl
exert
protect
effect
inhibit
product
inhibit
tolllik
receptor
howev
studi
shown
outbreak
ks
patient
take
blocker
infliximab
case
question
role
factor
genesi
diseas
especi
regard
role
product
inhibit
reactiv
lytic
cycl
gener
ks
pathogenesi
concern
ace
inhibitor
studi
suggest
protect
role
play
drug
result
improv
regress
ks
lesion
patient
administ
ace
inhibitor
matter
controversi
opposit
mechan
action
protect
induc
alleg
tabl
base
assess
possibl
hypothes
role
cofactor
ks
pathogenesi
move
toward
effect
either
favor
inhibit
onset
diseas
depend
presenc
agent
modul
pathogenesi
genet
predisposit
environment
factor
drug
intak
lymphat
system
disord
possibl
agent
may
act
either
stimul
inhibit
cofactor
base
patient
genet
background
variabl
interact
due
ks
heterogen
standard
therapeut
guidelin
sever
differ
therapeut
option
avail
ks
treatment
treatment
decis
must
take
consider
extent
rate
tumor
growth
patient
symptom
immun
system
condit
concurr
hivrel
complic
best
therapeut
result
obtain
classic
ks
local
treatment
iatrogen
ks
usual
regress
withdraw
culprit
drug
endem
ks
may
requir
system
therapi
cytostat
agent
result
variabl
outcom
depend
extent
sever
diseas
epidem
ks
preval
decreas
dramat
sinc
introduct
highli
activ
antiretrovir
therapi
haart
therapeut
option
distinguish
two
group
local
system
therapi
local
therapi
allow
safe
costeffect
approach
reserv
patient
minim
cutan
diseas
nonrespond
system
therapi
rapidli
progress
diseas
palli
therapi
intralesion
vinblastin
oral
etoposid
cryotherapi
liquid
nitrogen
excision
surgeri
may
feasibl
option
alitretinoid
gel
acid
may
appli
two
four
time
daili
affect
area
overal
respons
rate
orr
rang
cutan
reaction
electrochemotherapi
ect
emerg
treatment
cutan
lesion
differ
tumor
type
combin
chemotherapi
electropor
enhanc
drug
uptak
radiotherapi
effect
often
repres
best
local
treatment
palliat
pain
bleed
edema
respons
complet
remiss
rate
respect
patient
far
advanc
diseas
singl
dose
gy
prefer
system
therapi
haart
haart
indispens
treatment
epidem
ks
patient
alon
combin
system
chemotherapi
local
therapi
antiretrovir
drug
foscarnet
ganciclovir
cidofovir
adefovir
alleg
activ
patient
limit
cutan
lesion
earlystag
diseas
andor
slowli
prolifer
diseas
effect
haart
regimen
may
repres
first
step
therapi
ks
orr
complet
remiss
rate
ks
lesion
typic
start
decreas
disappear
complet
within
week
month
frequent
ks
may
flare
dramat
follow
initi
haart
seem
manifest
immun
reconstitut
inflammatori
syndrom
iri
occur
hivposit
patient
initi
low
count
incontrol
viral
load
present
haart
alon
may
repres
firstlin
therapi
slowli
progress
diseas
haart
concomit
chemotherapi
indic
viscer
andor
rapidli
progress
diseas
wherea
haart
system
chemotherapi
may
effect
antik
therapi
debunk
chemotherapi
orr
system
chemotherapi
system
chemotherapi
reserv
patient
respond
haart
andor
widespread
symptomat
rapidli
progress
lifethreaten
diseas
viscer
involv
irisassoci
flare
sever
singleag
therapi
report
activ
aidsrel
ks
vincristin
vinblastin
vinorelbin
etoposid
teniposid
adriamycin
epirubicin
bleomycin
docetaxel
paclitaxel
orr
rang
although
partial
respons
liposom
anthracyclin
doxorubicin
daunorubicin
consid
firstlin
therapi
patient
advanc
aidsk
paclitaxel
cytotox
agent
exert
antitumor
activ
polymer
microtubul
inhibit
cell
divis
reserv
patient
recurr
refractori
aidsrel
ks
firstlin
chemotherapi
intraven
paclitaxel
mgm
given
everi
week
infus
associ
respons
rate
durat
sustain
respons
month
highdos
allow
obtain
complet
partial
respons
rate
count
greater
current
understand
ks
converg
immun
evas
oncogenesi
inflamm
angiogenesi
prompt
investig
develop
target
therapi
base
antiangiogen
agent
metalloproteinas
inhibitor
cytokin
signal
therapi
may
effect
strategi
patient
epidem
ks
progress
despit
chemotherapi
andor
haart
irinotecan
semisynthet
camptothecin
deriv
convert
decarboxyl
biolog
activ
form
belong
recent
establish
class
anticanc
agent
cytotox
mechan
target
cellular
enzym
dna
topoisomeras
model
fibroblast
growth
angiogenesi
mous
cornea
suggest
irinotecan
may
activ
also
ks
data
gicat
gruppo
italiano
cooperativo
aid
e
tumori
phase
ii
studi
show
intraven
mgm
day
mgm
everi
day
plu
haart
includ
proteas
inhibitor
activ
well
toler
hivinfect
patient
ks
relaps
progress
haart
matrix
metalloproteinas
mmp
constitut
overexpress
ks
cell
famili
zincdepend
endopeptidas
involv
degrad
collagen
iv
major
compon
basement
membran
facilit
tumor
invas
metastas
phase
ii
trial
data
shown
mg
mmp
inhibitor
block
vitro
activ
neutrophil
gelatinas
express
mmp
human
colon
breast
cancer
cell
line
dosedepend
manner
administ
oral
daili
produc
signific
declin
mmp
level
orr
median
durat
respons
week
thalidomid
mgday
month
shown
block
product
inhibit
basement
membran
format
intercellular
adhes
molecul
inhibit
vascular
endotheli
cell
prolifer
induc
thalidomid
occur
associ
mark
decreas
activ
transcript
factor
involv
extracellular
matrix
gene
express
moder
inhibit
nuclear
activ
nuclear
extract
cytochin
enhanc
type
immun
downregul
constitut
activ
g
proteicoupl
receptor
encod
accord
preliminari
result
phase
studi
combin
plu
liposom
doxorubicin
haart
remiss
obtain
substanti
percentag
patient
advanc
ks
oral
imatinib
mesyl
mg
twice
daili
inhibit
activ
plateletderiv
growth
factor
ckit
receptor
import
target
mediat
growth
aidsrel
ks
latest
decad
pathogenesi
ks
greatli
elucid
new
etiolog
factor
describ
facilit
develop
effect
therapeut
approach
mani
aspect
ks
still
remain
unsolv
studi
need
matter
